جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

23 مُخرَج نتائج البحث عن «Drug development»

مقالوصول مفتوح2026

In silico assessment of catenulopyrizomicin A and B as potential inhibitors of HCV NS3/4A protease

Discover Applied Sciences

The hepatitis C virus (HCV) has no vaccine, and available therapies are linked to adverse outcomes, high costs and emergence of resistance. A previous study have identified catenulopyrizomicin A and B as bioactive compounds from natural products with reported antiviral properties, warranting further evaluation against the HCV NS3/4A protease using non-in silico methods. The aim of this study was to evaluate the anti-HCV potentials of catenulopyrizomicins A and B against 5EQS, a genotype 1a/3a chimeric HCV NS3/4A protease of HCV using in silico approaches. In this study, the anti-HCV potential of catenulopyrizomicin A and B was evaluated using in silico approaches (molecular docking, simulation, ADMET profiling, and DFT) with ribavirin as a control, and 5EQS as the target protein (NS3/4A). Docking scores for the ligands were − 5.8, − 5.8, and − 6.1 kcal/mol, respectively, for catenulopyrizomicin B, ribavirin, and catenulopyrizomicin A. Two dimensional (2D) visualisation of the formed complexes revealed the dominance of Van der Waals forces and polar interactions between the ligands and the target protein. Molecular dynamics simulations revealed variations in RMSD and RMSF that indicated that the formed stable complexes with values that remained below 2.0 Å throughout most of the simulation runs, indicating stability. Ligand-protein contact analysis revealed the presence of conserved residues, including Gln1041, Thr1042, His1057, Arg1109, Leu1132, Leu1135, Lys1136, and Cys1159 across the test ligands, suggesting that they may be important in ligand recognition and foramtion of stable interactions. ADMET properties revealed that catenulopyrizomicin A and B had better intestinal absorption rates (36.41% and 36.28%) than ribavirin (30.95%), as well as good distribution, as revealed by their better VDss values (− 0.53 to − 0.61 for catenulopyrizomicin A and B) compared to ribavirin which was − 0.22. The DFT results showed that catenulopyrizomicin A and B were more reactive and nucleophilic than ribavirin. The findings suggest that catenulopyrizomicin A and B may serve as potential lead compounds for anti-HCV drug development. However, further in vitro and in vivo studies are required to validate their antiviral activity and pharmacological properties.

hepatitis C virusNS3/4A proteaseprotease inhibitorsmolecular docking
مقالوصول مغلق20256استشهاد· Semantic Scholar

Development and evaluation of mucoadhesive buccal films for sustained release of glipizide using natural proteins

Drug Development and Industrial Pharmacy · مجلد 51 (8) · 930-942

PURPOSE: To address the challenges of frequent glipizide dosing, including its variable bioa-vailability and gastrointestinal side effects, this study developed and evaluated mucoadhesive buccal films using natural proteins (albumin, gelatin, casein) combined with HPMC E15 to achieve sustained drug delivery. METHODS: Nine formulations (F1-F9) were prepared using solvent casting technique and sys-tematically characterized. Comprehensive evaluations included: (1) drug-polymer compatibil-ity studies (FT-IR, DSC), (2) physicochemical characterization (thickness, weight uniformity, swelling index, moisture content, folding endurance, surface pH), (3) ex-vivo permeation studies through sheep buccal mucosa, and (4) stability assessments to determine film longevi-ty. RESULTS: Compatibility studies utilizing FT-IR and DSC confirmed no significant incompati-bility between glipizide and the excipients. Some of the important physicochemical character-istics recorded for different formulations were surface pH (6.6 - 6.8), folding endurance (72 - 184), moisture content (5.66 - 12.54%), thickness (0.171 - 0.236 mm), weight (0.150 - 0.238 mg), and swelling index (15.8% after 1 hour to 86.6% after 5 hours). Furthermore, neg-ligible variation was observed in these characteristics when stability studies were conducted after 3 months. The ex-vivo permeation studies demonstrated a sustained release of glipizide over 8 hours, with release percentages ranging from 80.94% to 90%. Formulation F6, which achieved an 8-hour release of 89.29%, was identified as optimal. Kinetic analysis revealed zero-order release kinetics for all formulations. CONCLUSION: The developed mucoadhesive buccal films exhibited excellent sustained-release properties, representing a significant improvement over conventional dosage forms. This in-novative delivery system shows strong potential for enhancing diabetes management through improved bioavailability and patient compliance, while minimizing gastrointestinal side effects.

mucoadhesive buccal filmsglipizidesustained drug releasenatural proteins
مقالوصول مفتوح20255استشهاد· Semantic Scholar

Exploration of effective pharmacological inhibitors for NS5 protein through computational approach: A strategy to combat the neglected Kyasanur forest disease virus

PLoS ONE · مجلد 20 (7) · e0325613-e0325613

Kyasanur Forest Disease Virus (KFDV) poses a significant public health threat due to the limited efficacy of existing vaccines, necessitating the development of effective antiviral therapeutics. The nonstructural protein 5 (NS5), essential for viral RNA synthesis and methylation, serves as a promising drug target. This study employs computational approaches to identify and evaluate potential NS5 inhibitors that may contribute to the development of antiviral compounds against KFDV. The 3D structure of NS5 was predicted using Robetta, SwissModel, and I-TASSER, with the Robetta model (ERRAT score: 96.40) selected for energy minimization. The globally minimized structure, obtained at 49.58 ns, had a potential energy of -416966.82 kcal/mol and was used for further studies. Active site residues were identified using template-based and structure-based methods (COACH-D, CASTp, PrankWeb) and were located within polymerase motif (A-G) of NS5 protein (residues 273-903 aa), which are essential for polymerase function, RNA synthesis, and viral replication. A total of 1523 compounds were identified using de novo, template-based design, pharmacophore modeling, and ligand screening. Virtual screening with PyRx 0.8 yielded 34 promising compounds, of which 11 were selected based on molecular docking (AutoDock 4.0) with binding energies of -8.86 kcal/mol (FDA-approved dasabuvir -L1), -8.28 kcal/mol (CNPO331352.1-L2), -7.94 kcal/mol (ZINC00103114410- L3), and -7.61 kcal/mol (CNPO202263.1-L4). MD simulations in triplicates under physiological conditions confirmed stability. with MM-GBSA binding free energy values of -52.28 ± 2.91 kcal/mol (NS5-Dasabuvur L1complex), -46.82 ± 4.31 kcal/mol (NS5-L2 complex), -50.72 ± 6.36 kcal/mol (NS5-L3 complex), and -57.03 ± 4.31 kcal/mol (NS5-L4 complex). The computational analysis suggests that compounds L2 and L4 have strong binding affinities comparable to dasabuvir (L1), indicating their potential as inhibitors of the KFDV NS5 protein. Further validation through in vitro assays would complement these in silico findings. These results provide a foundation for future drug development against KFDV, emphasizing the need for continued exploration of antiviral therapeutics.

Kyasanur forest disease virusNS5 proteinRNA-dependent RNA polymeraseantiviral drug design
مقالوصول مغلق20252استشهاد· Semantic Scholar

Target‐Specific Potency and Drug‐Ability Profile of Flavonoids Against Lung Cancer: An Integrative Multi‐Omics Approach for Lead Identification

Drug Development Research · مجلد 86 (5) · e70131-e70131

Since lung cancer accounts for approximately 20% of cancer-related fatalities globally, it is one of the most common and deadly cancers, necessitating the discovery of innovative, potent, and less toxic treatment agents as imperative. Opportunistically, phytoflavonoids (PFs), a specific class of phytochemicals, display promising anticancer activity through their multimodal apoptosis-inducing properties. Based on existing evidence, the present study employs an integrative multi-omics approach to assess the target-specific binding efficacy and drug-ability outlines of PFs against lung cancer. We selected two of the most likely lung cancer targets using the core part of PFs: carbonic anhydrase IX (PDB ID: 3DAZ) and poly(A) binding protein cytoplasmic 1 (PDB ID: 3KUJ). Another two key targets, glutathione S-transferase P1 (PDB ID: 3GSS) and 17β-hydroxysteroid dehydrogenase 1 (HSD17B1, 3HB4), were also included in our study based on recent literature. The potency of 66 PFs against four targets was assessed through a molecular docking study using PyRx 0.8-AutoDock 4.2 software. PF15, PF43, PF6, and PF26 were the lead candidates. Further, physicochemical profiles through standard Lipinski rule of five parameters and toxicity and drug-ability profiles suggested that PF43 (naringenin) is the most ideal lead candidate among them. Molecular dynamics (MD) simulation studies were performed at 200 ns to observe the kinetic behaviors of CA9-PF43 and CA9-U-1014 docking complexes along with the calculated free energy through the MM/PBSA method. From both analyses, PF43 showed higher stability and lower free energy, expressing its potency over the standard drug. We also investigated the structure-activity relationship and frontier molecular orbitals to highlight the drug chemistry of lead PFs. The integrative multi-omics investigation suggested that using PF43 for lung cancer treatment could increase the chances of experimental success. Overall, the systematic computational analyses provide a platform for lead identification and pave the way for precision phytotherapy in current drug discovery.

lung cancerflavonoidsnaringenincarbonic anhydrase IX
مقالوصول مفتوح20251استشهاد· Semantic Scholar

Exploring phytochemicals as potential pharmacological inhibitors for NS1 protein of Kyasanur forest disease virus using virtual screening, molecular docking, and molecular simulation approach

PeerJ · مجلد 13 · e19954-e19954

Background: Kyasanur forest disease virus (KFDV) remains a significant public health challenge due to the limitations of existing vaccines, creating a critical need for effective antiviral treatments. KFDV is a tick-borne virus responsible for 400-500 new cases annually, with a mortality rate of 3-5%. The nonstructural protein 1 (NS1), which plays crucial roles in host cell interactions, immune evasion, and viral replication, represents a promising target for antiviral drug development. Objective: This study aims to identify potential antiviral compounds that inhibit the activity of KFDV NS1 protein using a computational pharmacological drug design approach. The objectives include determining the 3D structure of the NS1 protein through homology modeling, conducting virtual screening of phytochemicals to identify potential inhibitors, and performing molecular dynamics simulations to assess the stability and binding free energies of the selected compounds. Methods: The 3D structure of KFDV NS1 protein was predicted using homology modeling and validated using Ramachandran plot analysis. Virtual screening of phytochemicals from the Indian Medicinal Plants, Phytochemistry And Therapeutics (IMPPAT) database was performed to identify potential NS1 inhibitors. The top 15 compounds with the highest binding affinities were selected and subjected to absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis. Molecular dynamics simulations were conducted in duplicates for 200 ns to evaluate the stability of the ligand-NS1 complexes, and an additional independent simulation with randomized initial velocities was performed to ensure statistical robustness. Binding free energies were calculated using the molecular mechanics-generalized born surface area (MM-GBSA) method to determine the binding strength of each compound. Results: The 3D structure of the KFDV NS1 protein was determined using I-Tasser-MTD, Robetta, and Swiss Model servers, and a minimized model of I-Tasser, achieving an ERRAT score of 94.37, was selected. Virtual screening of 11,530 phytochemicals from the IMPPAT database identified the top 115 compounds after three screening phases. Out of the 15 screened compounds, L2, L3, and L5 demonstrated notable binding affinities of -9.34, -9.12, and -9.08 kcal/mol, respectively, compared to the FDA-approved antiviral dasabuvir, which had a binding affinity of -8.0 kcal/mol. Molecular dynamics simulations confirmed the stability of compounds L2 (IMPHY010294), L3 (IMPHY001281), L5 (IMPHY011162), and dasabuvir, with free-energy binding values of -62.97 ± 4.0, -77.22 ± 4.71, -62.07 ± 2.88, and -87.68 ± 4.31 kcal/mol, respectively. Conclusion: findings.

Kyasanur forest disease virusNS1 proteinantiviral drug designphytochemicals
مقالوصول مفتوح202412استشهاد· Semantic Scholar

Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach

Antiviral Therapy · مجلد 29 (6) · 13596535241305536-13596535241305536

Background The COVID-19 pandemic has created an urgent need for effective therapeutic agents. The SARS-CoV-2 Main Protease (M pro ) plays a crucial role in viral replication and immune evasion, making it a key target for drug development. While several studies have explored M pro inhibition, identifying FDA-approved drugs with potential efficacy remains a critical research focus. Purpose This study aims to identify FDA-approved drugs that could inhibit SARS-CoV-2 M pro . Using computational screening, we seek compounds that share structural similarities with a known co-crystallized ligand (PRD_002214) and exhibit strong binding affinity to the enzyme, providing viable candidates for COVID-19 treatment. Research Design A systematic in silico approach was used, screening 3009 FDA-approved drugs. The initial screening focused on structural similarity to PRD_002214 (PDB ID: 6LU7), followed by molecular docking studies to predict binding affinity. Promising compounds were further analyzed through molecular dynamics (MD) simulations to evaluate their stability and interactions with M pro over 100 ns. Study Sample Of the 3009 FDA-approved drugs screened, 74 were selected for initial evaluation. After refinement, 28 compounds underwent docking analysis, with eight showing strong binding potential to M pro . Analysis Molecular docking assessed the binding affinity and interaction of the selected compounds with M pro . MD simulations were conducted on the top compound, Atazanavir, to study its dynamic interactions. MM-GBSA, PLIP, and PCAT analyses were used to validate binding affinity and interactions. Results Eight compounds, including Carfilzomib, Atazanavir, Darunavir, and others, exhibited promising binding affinities. Among them, Atazanavir showed the highest binding strength and was selected for further MD simulation studies. These simulations revealed that Atazanavir forms stable interactions with M pro , demonstrating favorable binding and dynamic stability. The binding affinity was further confirmed through MM-GBSA, PLIP, and PCAT analyses, supporting Atazanavir's potential as an effective M pro inhibitor. Conclusions In silico results suggest that Atazanavir is a promising candidate for targeting SARS-CoV-2 M pro , with strong binding affinity and dynamic stability. These findings support its potential as a lead compound for further preclinical and clinical testing, though in vitro and in vivo validation are needed to confirm its therapeutic efficacy against COVID-19.

COVID-19 pandemicmain proteaseMpro inhibitorsFDA-approved drugs
مقالوصول مفتوح202412استشهاد· Semantic Scholar

Structure-based discovery of F. religiosa phytochemicals as potential inhibitors against Monkeypox (mpox) viral protein

Journal of Biosafety and Biosecurity · مجلد 6 (3) · 157-169

Outbreaks of Monkeypox (mpox) in over 100 non-endemic countries in 2022 represented a serious global health concern. Once a neglected disease, mpox has become a global public health issue. A42R profilin-like protein from mpox (PDB ID: 4QWO) represents a potential new lead for drug development and may interact with various synthetic and natural compounds. In this report, the interaction of A42R profilin-like protein with six phytochemicals found in the medicinal plant Ficus religiosa (abundant in India) was examined. Based on the predicted and compared protein-ligand binding energies, biological properties, IC50 values and toxicity, two compounds, kaempferol (C-1) and piperine (C-4), were selected. ADMET characteristics and quantitative structure-activity relationship (QSAR) of these two compounds were determined, and molecular dynamics (MD) simulations were performed. In silico examination of the kaempferol (C-1) and piperine (C-4) interactions with A42R profilin-like protein gave best-pose ligand-binding energies of –6.98 and –5.57 kcal/mol, respectively. The predicted IC50 of C-1 was 7.63 μM and 82 μM for C-4. Toxicity data indicated that kaempferol and piperine are non-mutagenic, and the QSAR data revealed that piperlongumine (5.92) and piperine (5.25) had higher log P values than the other compounds examined. MD simulations of A42R profilin-like protein in complex with C-1 and C-4 were performed to examine the stability of the ligand-protein interactions. As C-1 and C-4 showed the highest affinity and activities, they may be suitable lead candidates for developing mpox therapeutic drugs. This study should facilitate discovering and synthesizing innovative therapeutics to address other infectious diseases.

monkeypoxFicus religiosaphytochemicalskaempferol
مقالوصول مفتوح202411استشهاد· Semantic Scholar

DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras

PLoS ONE · مجلد 19 (3) · e0300035-e0300035

The development of effective drugs targeting the K-Ras oncogene product is a significant focus in anticancer drug development. Despite the lack of successful Ras signaling inhibitors, recent research has identified PDEδ, a KRAS transporter, as a potential target for inhibiting the oncogenic KRAS signaling pathway. This study aims to investigate the interactions between eight K-Ras inhibitors (deltarazine, deltaflexin 1 and 2, and its analogues) and PDEδ to understand their binding modes. The research will utilize computational techniques such as density functional theory (DFT) and molecular electrostatic surface potential (MESP), molecular docking, binding site analyses, molecular dynamic (MD) simulations, electronic structure computations, and predictions of the binding free energy. Molecular dynamic simulations (MD) will be used to predict the binding conformations and pharmacophoric features in the active site of PDEδ for the examined structures. The binding free energies determined using the MMPB(GB)SA method will be compared with the observed potency values of the tested compounds. This computational approach aims to enhance understanding of the PDEδ selective mechanism, which could contribute to the development of novel selective inhibitors for K-Ras signaling.

PDEδKRAS inhibitorsoncogenic KRASbinding free energy
مقالوصول مفتوح202410استشهاد· Semantic Scholar

Computational exploration of Picrasma quassioides compounds as CviR-mediated quorum sensing inhibitors against Chromobacterium violaceum

Frontiers in Chemistry · مجلد 12 · 1286675-1286675

Chromobacterium violaceum an opportunistic human pathogenic bacterium, exhibits resistance to conventional antibiotics by exploiting its quorum sensing mechanism to regulate virulence factor expression. In light of this, disrupting the quorum sensing mechanism presents a promising avenue for treating infections caused by this pathogen. The study focused on using the cytoplasmic quorum sensing receptor CviR from C. violaceum as a model target to identify novel quorum sensing inhibitors from P. quassioides through in silico computational approaches. Molecular docking analyses unveiled that several phytochemicals derived from Picrasma quassioides exhibit the potential to inhibit quorum sensing by binding to CviR protein. Notably, the compounds such as Quassidine I (– 8.8 kcal/mol), Quassidine J (– 8.8 kcal/mol), Kumudine B (– 9.1 kcal/mol) and Picrasamide A (– 8.9 kcal/mol) exhibited high docking scores, indicating strong binding affinity to the CviR protein. The native ligand C6-HSL (N-hexanoyl-L-homoserine lactone) as a positive control/co-crystal inhibitor also demonstrated a significant binding energy of—7.7 kcal/mol. The molecular dynamics simulation for 200 ns showed the thermodynamic stability and binding affinity refinement of the top-ranked CviR inhibitor (Kumudine B) with its stable binding and minor fluctuations compared to positive control (C6-HSL). Pharmacokinetic predictions indicated that Kumudine B possesses favourable drug-like properties, which suggest its potential as a drug candidate. The study highlight Kumudine B as a potential agent for inhibiting the CviR protein in C. violaceum. The comprehensive evaluation of Kumudine B provides valuable insights into its pharmacological profiles, facilitating its assessment for diverse therapeutic applications and guiding future research activities, particularly as antibacterial agents for clinical drug development.

Picrasma quassioidesChromobacterium violaceumquorum sensing inhibitionphytochemicals
مقالوصول مغلق20244استشهاد· Semantic Scholar

In-silico and in-vitro evaluation of antifungal bioactive compounds from Streptomyces sp. strain 130 against Aspergillus flavus

Journal of Biomolecular Structure and Dynamics · مجلد 43 (12) · 6045-6063

Streptomyces spp. are considered excellent reservoirs of natural bioactive compounds. The study evaluated the bioactive potential of secondary metabolites from Streptomyces sp. strain 130 through PKS-I and NRPS gene-clusters screening. GC-MS analysis was done for metabolic profiling of bioactive compounds from strain 130 in the next set of experiments. Identified antifungal compounds underwent ADMET analyses to screen their toxicity. All compounds’ molecular docking was done with the structural gene products of the aflatoxin biosynthetic pathway of Aspergillus flavus. MD simulations were utilized to evaluate the stability of protein-ligand complexes under physiological conditions. Based on the in-silico studies, compound 2,4-di-tert butyl-phenol (DTBP) was selected for in-vitro studies against Aspergillus flavus. Simultaneously, bioactive compounds were extracted from strain 130 in two different solvents (ethyl-acetate and methanol) and used for similar assays. The MIC value of DTBP was found to be 314 µg/mL, whereas in ethyl-acetate extract and methanol-extract, it was 250 and 350 µg/mL, respectively. A mycelium growth assay was done to analyze the effect of compounds/extracts on the mycelium formation of Aspergillus flavus. In agar diffusion assay, zone of inhibitions in DTBP, ethyl-acetate extract, and methanol extract were observed with diameters of 11.3, 13.3, and 7.6 mm, respectively. In the growth curve assay, treated samples have delayed the growth of fungi, which signified that the compounds have a fungistatic nature. Spot assay has determined the fungal sensitivity to a sub-minimum inhibitory concentration of antifungal compounds. The study’s results suggested that DTBP can be exploited for antifungal-drug development.Communicated by Ramaswamy H. Sarma

StreptomycesAspergillus flavusantifungal agents2,4-di-tert-butylphenol
مقالوصول مغلق20242استشهاد· Semantic Scholar

New Thieno[2,3-d]pyrimidines as Anticancer VEGFR-2 Inhibitors with Apoptosis Induction: Design, Synthesis, and Biological and In Silico Studies

Medicinal Chemistry · مجلد 20 (9) · 876-899

Background: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a critical protein involved in tumor progression, making it an attractive target for cancer therapy. Objective: This study aimed to synthesize and evaluate novel thieno[2,3-d]pyrimidine analogues as potential anticancer VEGFR-2 inhibitors. Methods: The thieno[2,3-d]pyrimidine analogues were synthesized following the pharmacophoric features of VEGFR-2 inhibitors. The anticancer potential was assessed against PC3 and HepG2 cell lines. The VEGFR-2 inhibition was evaluated through IC50 determination. Cell cycle analysis and apoptosis assays were performed to elucidate the mechanisms of action. Molecular docking, molecular dynamics simulations, MM-GBSA, and PLIP studies were conducted to investigate the binding affinities and interactions with VEGFR-2. Additionally, in silico ADMET studies were performed. Results: Compound 8b demonstrated significant anti-proliferative activities with IC50 values of 16.35 μM and 8.24 μM against PC3 and HepG2 cell lines, respectively, surpassing sorafenib and exhibiting enhanced selectivity indices. Furthermore, compound 8b showed an IC50 value of 73 nM for VEGFR-2 inhibition. Cell cycle analysis revealed G2-M phase arrest, while apoptosis assays demonstrated increased apoptosis in HepG2 cells. Molecular docking and dynamic simulations confirmed the binding affinity and interaction of compound 8b with VEGFR-2, supported by MMGBSA and PLIP studies. In silico ADMET studies indicated the drug development potential of the synthesized thieno[2,3-d]pyrimidines. Conclusion: The study highlights compound 8b as a promising VEGFR-2 inhibitor with potent anti-proliferative activities. Its mechanism of action involves cell cycle arrest and induction of apoptosis. Further, molecular docking and dynamic simulations support the strong binding affinity of compound 8b to VEGFR-2.

thieno[2,3-d]pyrimidinesVEGFR-2 inhibitorsanticancer agentsapoptosis induction
مقالمفتوح (مستودع)20241استشهاد· Semantic Scholar

An evaluation of the precision of computational methods used in drug development initiatives

Journal of Biomolecular Structure and Dynamics · مجلد 44 (5) · 2235-2249

Computational approaches are commonly employed to expedite and provide decision-making for the drug development process. Drug development programs that involve targets without known crystal structures can be quite challenging. In many cases, a viable approach is to generate reliable homology models using the amino acid sequence of the target. This is followed by a series of validation steps, druggable pocket detection, and then moving forward with lead identification and validation. This study commenced by conducting an initial benchmark exercise using a series of computationally designed sequences for steroid-binding proteins. By conducting an unbiased comparison with the released X-ray crystal structures, the homology models that were generated demonstrated reliable outcomes. The aligned homology models showed a root mean square deviation (RMSD) of less than 0.6 Å when compared to the corresponding X-ray structures. Three different methods were used to detect the druggable cavities for comparison, and the identified pockets closely resembled those of the crystal structures. The achievement of near-native pose prediction was made possible by utilizing the comprehensive binding energy function that characterizes the interaction between each pose and the neighboring residues. In order to address the issue of limited correlation between entropy and internal energy in docking, an alternative was devised by incorporating entropy as a post-docking optimization step to enhance the accuracy of ligand binding affinity predictions and improve the overall quality of the results.

homology modelingsteroid binding proteinsmolecular dockingbinding affinity prediction
مقالوصول مغلق202327استشهاد· Semantic Scholar

New Theobromine Derivatives Inhibiting VEGFR-2: Design, Synthesis, Antiproliferative, Docking and Molecular Dynamics Simulations

Future Medicinal Chemistry · مجلد 15 (14) · 1233-1250

Background: VEGFR-2 is one of the most effective targets in cancer treatment. Aim: The design and semi-synthesis of new theobromine derivatives as potential VEGFR-2 inhibitors. Methods: In vitro and in silico evaluation of the synthesized compounds. Results: Compound 5b demonstrated excellent antiproliferative and VEGFR-2 inhibitory effects with significant apoptotic activity. It modulated the immune response by increasing IL-2 and reducing TNF-α levels. Docking and molecular dynamics simulations revealed the compound’s binding affinity with VEGFR-2. Lastly, computational absorption, distribution, metabolism, excretion and toxicity studies indicated the high potential of compound 5b for drug development. Conclusion: Compound 5b could be a promising anticancer agent targeting VEGFR-2.

theobromine derivativesVEGFR-2 inhibitorsantiproliferative activityapoptosis
مقالوصول مفتوح202313استشهاد· Semantic Scholar

Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach

Antiviral Therapy · مجلد 28 (5) · 13596535231199838-13596535231199838

Background The COVID-19 pandemic has led to significant loss of life and economic disruption worldwide. Currently, there are limited effective treatments available for this disease. SARS-CoV-2 RNA-dependent RNA polymerase (SARS-CoV-2 RdRp) has been identified as a potential target for drug development against COVID-19. Natural products have been shown to possess antiviral properties, making them a promising source for developing drugs against SARS-CoV-2. Objectives The objective of this study is to identify the most effective natural inhibitors of SARS-CoV-2 RdRp among a set of 4924 African natural products using a multi-phase in silico approach. Methods The study utilized remdesivir (RTP), the co-crystallized ligand of RdRp, as a starting point to select compounds that have the most similar chemical structures among the examined set of compounds. Molecular fingerprints and structure similarity studies were carried out in the first part of the study. The second part of the study included molecular docking against SARS-CoV-2 RdRp (PDB ID: 7BV2) and Molecular Dynamics (MD) simulations including the calculation of RMSD, RMSF, Rg, SASA, hydrogen bonding, and PLIP. Moreover, the calculations of Molecular mechanics with generalised Born and surface area solvation (MM-GBSA) Lennard-Jones and Columbic electrostatic interaction energies have been conducted. Additionally, in silico ADMET and toxicity studies were performed to examine the drug likeness degrees of the selected compounds. Results Eight compounds were identified as the most effective natural inhibitors of SARS-CoV-2 RdRp. These compounds are kaempferol 3-galactoside, kaempferol 3- O- β-D-glucopyranoside, mangiferin methyl ether, luteolin 7- O- β-D-glucopyranoside, quercetin- O- β-D-3-glucopyranoside, 1-methoxy-3-indolylmethyl glucosinolate, naringenin, and asphodelin A 4’- O- β-D-glucopyranoside. Conclusion The results of this study provide valuable information for the development of natural product-based drugs against COVID-19. However, the elected compounds should be further studied in vitro and in vivo to confirm their efficacy in treating COVID-19.

COVID-19 pandemicnatural product inhibitorsremdesivirstructural similarity
مقالوصول مفتوح20238استشهاد· Semantic Scholar

Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi

Microbiology Spectrum · مجلد 11 (4) · e0267922-e0267922

The drug repurposing strategy is an alternative approach to reducing drug development timelines with low cost, especially during outbreaks of disease caused by drug-resistant pathogens. Rafoxanide can disrupt the abilities of bacterial and fungal cells to adapt to stress conditions. The coadministration of antibiotics with rafoxanide can prevent the failure of treatment of both resistant bacteria and fungi, as the resistant pathogens could be made sensitive upon treatment with rafoxanide. From our findings, we anticipate that pharmaceutical companies will be able to utilize new combinations against resistant pathogens.

rafoxanidedrug repurposingantimicrobial resistancedrug-resistant bacteria